Solventum Corp: insider trades · United States · SEC (Form 4)

About Solventum Corp

Solventum Corp. (NYSE: SOLV) is a U.S.-listed healthcare company traded on the New York Stock Exchange in the United States, with headquarters in St. Paul, Minnesota, United States. The company became an independent public entity after the spin-off of 3M’s healthcare business was completed on April 1, 2024. Although Solventum is young as a standalone corporation, its operating heritage is much older, reflecting decades of development within 3M Health Care and a legacy of applied materials science, clinical know-how, and product innovation. ([solventum.com](https://www.solventum.com/en-ca/home/our-company/newsroom/press-releases/2024-04-01-solventum-begins-trading-on-the-new-york-stock-exchange/?utm_source=openai)) From a business perspective, Solventum operates as a diversified healthcare platform serving medical-surgical, dental, and health information technology customers. Its portfolio includes wound care and surgical solutions, infection prevention and other hospital consumables, dental restoratives and orthodontic materials, and digital health / clinical information systems that support healthcare workflows and data management. This mix gives the company exposure to recurring healthcare demand across providers, hospitals, clinics, and dental practices, while also tying it to regulated end markets where product quality and compliance are essential. ([solventum.com](https://www.solventum.com/en-us/home/our-company/leadership/?utm_source=openai)) Competitively, Solventum benefits from a strong installed base, trusted brands, and the technical depth inherited from 3M’s healthcare operations. Management positions the company as a global healthcare leader operating at the intersection of health, material science, and data science. That said, the competitive environment remains intense, with pressure from other medtech players, dental-product suppliers, and healthcare IT vendors, alongside ongoing regulatory, reimbursement, supply-chain, and product-liability risks typical of the sector. ([solventum.com](https://www.solventum.com/en-us/home/our-company/leadership/?utm_source=openai)) Geographically, Solventum is global, although investor communications continue to emphasize its U.S. base and international commercial reach. A key strategic development in 2025 was the announced sale of its Purification & Filtration business to Thermo Fisher Scientific for $4.1 billion. Management said the divestiture would sharpen the company’s focus on priority growth areas and support debt reduction. During 2025, Solventum also reported improving operating momentum, with positive organic growth, raised guidance, and a multi-year “Transform for the Future” initiative designed to improve execution and long-term value creation. ([investors.solventum.com](https://investors.solventum.com/news-events/press-releases/detail/99/solventum-announces-sale-of-its-purification-filtration-business-to-thermo-fisher-scientific-inc-for-4-1b?utm_source=openai)) For French-speaking investors, Solventum is best viewed as a post-spin healthcare restructuring story: a NYSE-listed U.S. company with a strong inherited franchise, broad healthcare exposure, and a more focused portfolio after recent divestiture activity. The key investment questions are execution of the transformation plan, margin discipline, balance-sheet repair, and the company’s ability to convert its technical heritage into sustained organic growth. ([investors.solventum.com](https://investors.solventum.com/news-events/press-releases/detail/143/solventum-reports-fourth-quarter-2025-financial-results-and-introduces-2026-full-year-guidance?utm_source=openai))